## **Table of contents**

## **List of Tables**

1	Raceline Characteric	tice			 7
1	Dascinic Characteris	itios .	 	 	 



**Baseline Characteristics Table** 

Generated with R and Quarto

Table 1: Baseline Characteristics

	Treatment Received				
Variable	Fakemethaline 150 mg N = 132	Fakemethaline 50 mg N = 134	Placebo N = 134	Overall N = 400	
Age					
Mean (SD)	35 (8)	34 (7)	35 (8)	35 (7)	
(Q1, Q3)	(30, 40)	(28, 39)	(30, 40)	(29, 39)	
Min, Max	20, 69	21, 50	21, 62	20, 69	
Age Group					
$\geq$ 17 to <65	131 (99%)	134 (100%)	134 (100%)	399 (100%)	
≥65	1 (0.8%)	0 (0%)	0 (0%)	1 (0.3%)	
Gender	,		, ,	, ,	
Female	70 (53%)	79 (59%)	82 (61%)	231 (58%)	
Male	62 (47%)	55 (41%)	52 (39%)	169 (42%)	
Race	. ,	, ,			
American Indian Or Alaska Native	6 (4.5%)	8 (6.0%)	11 (8.2%)	25 (6.3%)	
Asian	73 (55%)	68 (51%)	67 (50%)	208 (52%)	
Black Or African American	32 (24%)	31 (23%)	28 (21%)	91 (23%)	
Multiple	0 (0%)	0 (0%)	1 (0.7%)	1 (0.3%)	
Native Hawaiian Or Other Pacific Islander	0 (0%)	0 (0%)	1 (0.7%)	1 (0.3%)	
White	21 (16%)	27 (20%)	26 (19%)	74 (19%)	
Ethnicity	. ,	, ,			
Hispanic Or Latino	15 (11%)	15 (11%)	18 (13%)	48 (12%)	
Not Hispanic Or Latino	101 (77%)	104 (78%)	103 (77%)	308 (77%)	
Not Reported	11 (8.3%)	6 (4.5%)	10 (7.5%)	27 (6.8%)	
Unknown	5 (3.8%)	9 (6.7%)	3 (2.2%)	17 (4.3%)	
African American	32 (24%)	31 (23%)	28 (21%)	91 (23%)	

Table 1: Baseline Characteristics (continued)

	Treatment Received				
Variable	Fakemethaline 150 mg $N = 132$	Fakemethaline 50 mg N = 134	Placebo N = 134	Overall $N = 400$	
Region					
Africa	11 (8.3%)	8 (6.0%)	7 (5.2%)	26 (6.5%)	
Asia	83 (63%)	91 (68%)	94 (70%)	268 (67%)	
Eurasia	6 (4.5%)	5 (3.7%)	8 (6.0%)	19 (4.8%)	
Europe	2 (1.5%)	4 (3.0%)	3 (2.2%)	9 (2.3%)	
North America	20 (15%)	13 (9.7%)	15 (11%)	48 (12%)	
South America	10 (7.6%)	13 (9.7%)	7 (5.2%)	30 (7.5%)	
High Blood Pressure >(130/80)	79 (60%)	84 (63%)	92 (69%)	255 (64%)	
Weight Over 80kg	45 (34%)	39 (29%)	39 (29%)	123 (31%)	
¹ n (%)		,	, ,	, ,	